1. Selby JV, Ray GT, Zhang D, et al. Excess costs of medical care for patients with diabetes in managed care population. Diabetes Care. 1997; 20: 1396-1402. 1b. Berry J, Keebler Me, McGuire DK. Diabetes Mellitus and Cardiovascular Disease: Pandora's Box has been opened. Herz. 2004; 29(5): 456-62.
2b. Van Wijk I, Kappelle LJ, van Gijn J, Koudstaal PJ, Vermeulen G, Gorter JW, et al. Long-term survival and vascular event risk after transient ischemic attack or minor ischemic stroke: a cohort study. Lancet. 2005; 365(9477): 2098-104.10.1016/S0140-6736(05)66734-7
3. Sacco RL, Boden-Albala B, Abel G, Lin IF, Elkind M, Hause WA, et al. Race-ethnic disparities in in the impact of stroke risk factors in Northern Manhattan Stroke study. Stroke. 2001; 32: 1732-5. 3b. Mallick U, Dorobantu M, Iqbal B, Cheta D. An evidence based approach to the management of cardiovascular disease in Diabetes mellitus. In Cheta D. Vascular Involvment in Diabetes. Carger, Basel 2005.
4. Yamanouchi H, Shimada H, Kuramoto K. Subtypes and proportions of cerebrovascular disease in an autopsy series in a Japanese geriatric hospital. (Tokyo Metropolitan Geriatric Hospital series) Klin Wochenschr. 1990; 68: 1173-7.10.1007/BF018152732280580
5. Hillen T, Coshal C, Tilling K. on behalf of the South London Stroke register. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcome of stroke recurrence: The South London Stroke Register. Stroke. 2003; 34: 1457-63.10.1161/01.STR.0000072985.24967.7F12750544
6. Kuusisto J, Mykkanene L, Pyorala K, Laakso M. Noninsulin dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke. 1994; 25: 1157-64.10.1161/01.STR.25.6.1157
8. Karapanaytoides T, Piechowsky-Jozwiak B, van Melle G. Stroke patterns, ethiology and prognosis in patients with diabetes mellitus. Neurology. 2004; 62: 1558-62.10.1212/01.WNL.0000123252.55688.0515136681
9. Pinto A, Tuttolomondo A, Di Raimondo D, Di Sciacca R, Fernandez P, Di Gati M, et al. A case control study between diabetic and non-diabetic subjects with ischemic stroke. Int J Cardiol. 2008 Apr 25; 125(3):391-6.10.1016/j.ijcard.2007.03.10917490764
11. Mohave MR, Hashenmazadeh M, Jamal MM. Diabetes mellitus is a strong independent risk factor for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005; 105: 315-8.10.1016/j.ijcard.2005.02.05016274775
13. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995; 98: 476-84.10.1016/S0002-9343(99)80348-9
14. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994; 271: 840-44.10.1001/jama.1994.03510350050036
16. Arauz A, Murrillo L, Cantu C. Prospective study of single and multiple lacunar infarct using magnetic resonance imaging: risk factors, recurrence and outcome in 175 consecutive cases. Stroke. 2003; 34: 2453-8.10.1161/01.STR.0000090351.41662.9114500936
17. Rajala U, Laakso M, Painvansalo M. Blood pressure and atherosclerotic plaques in carotid, aortic and femoral arteries in elderly Finns with diabetes mellitus and impaired glucose tolerance. J Hum Hypertension. 2005; 19: 85-91.10.1038/sj.jhh.100177915343356
18. Henefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurtschiev T. Postchallenge hyperglycemia relates more strongly than fasting hyperglycemia with carotid intima-media thickness: the RIAD study Diabetic Med. 2000; 17: 835-40.
19. Hancu N, Cerghizam A. Global approach to Cardiovascular Risk in Type 2 Diabetic Persons. In: Hancu N. Cardiovascular Risk in Type 2 Diabetes mellitus. Springer Verlag Berlin, Heidelberg, New York. 2003: 240-76. 19b. Brohall G, Behre CJ, Hulthe J, Wikstrand J, Fagerberg B. Prevalence of diabetes mellitus and impaired glucose tolerance in 64-year-old Swedish women: experiences of using repeated oral glucose tolerance tests. Diabetes Care. 2006; 29: 363-7.10.2337/diacare.29.02.06.dc05-122916443888
20. 1 IRAS, 2 Kieschl S, Willeit J, for Bruneck Study Group. The natural course of atherosclerosis, part 1: incidence and progression. Arteriosc Thromb Vasc Biol. 1999; 34: 1484-90.
21. Selvin E, Coresh J, Golden SH. Glycemic control, Atherosclerosis, and Risk factors for cardiovascular Disease in Type 2 Diabetes. The Atherosclerosis Risk in Comunities Study. Diabetes Care. 2005; 28: 1963-75.
22. Göksan B, Erkol G, Bozluolcay M, Ince B. Diabetes as a determinant of high-grade carotid artery stenosis: Evaluation of 1,058 cases by Doppler sonography. J Stroke Cerebrovasc Dis. 2001; 10(6): 252-6.10.1053/jscd.2001.12377317903835
23. Yang B, Li TD, Wang JS, Zhi G, Jin WS, Xu Y. Insulin resistance and carotid atherosclerosis in 221 patients with potentional hyperglycemia. Chin Med Sci. 2005; 20(2): 108-11.
24. Baldassarre D, de Jong A, Amato M, Werba PJ, Castelnuovo S, Frigerio B, et al. Carotid intima-media thickness and markers of inflammation endothelial damage and hemostasis. Ann Med. 2007; 1-24.10.1080/0785389070164539917934910
25. Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Ca antagonist and ACE reduce IMT. Stroke. 2006 Jul; 37(7): 1933-40.10.1161/01.STR.0000227223.90239.1316763185
29. Lu W, Resnick HE, Jablonski KA, et al. Non-HDL Cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study. Diabetes Care. 2003; 26: 16-23.10.2337/diacare.26.1.1612502653
30. Jiang R, Schulze M, Li Tricia, et al. Non-HDL Cholesterol and Apoplipoprotein B Predict Cardiovascular Disease Events Among Men With Type 2 Diabetes. Diabetes Care; 2004: 27: 1991-7.10.2337/diacare.27.8.199115277429
31. De Vries R, Perton GF, Dallinga-Thie GM. Plasma cholesterol ester transfer is a determinant of intimamedia thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes. 2005; 54(12): 3554-9.10.2337/diabetes.54.12.355416306375
32. Kawamoto R, Tomita H, Oka Y, Kodama A, Kamitami A. Metabolic syndrome amplifies the LDL-cholesterol associated increases in carotid atherosclerosis. Intern Med. 2005; 44(12): 1232-8.10.2169/internalmedicine.44.123216415542
34. Rajala U, Laakso M, Paivansalo M. Low insulin sensitivity measured by both quantitative insulin sensitive check index and homeostasis model assessment method as a risk factor of increased intima-media thickness of the carotid artery. J Clin Endocrinol Metab. 2002; 87: 5092-7.10.1210/jc.2002-02070312414877
35. Szernichow S, Bertrais S, Oppert JM, Galan P, Blacher J, Ducimetiere P, et al. Body composition and after repartition in relation to structure and function of a large arteries in middle-aged adults (the SU.VI.MAX study). Int J Obes. 2005; 29: 826-32.
36. Nomura M, Kasamai R, Ohashi M, Ymada Y, Abe. H. Significantly higher invcidence of carotid atheroscelrotiss found in japanese type 2 diabetic patients with early nephropathy. Diabetes Res Clin Pract. 2004; 66(1): 161-3.10.1016/j.diabres.2003.09.01415563969
37. Zhang L, Zhao F, Yang Y, Qi L, Zhang B, Wang F, et al. Association between carotid artery intimamedia thickness and early-stage CKD in a Chinese population. Am J Kidney Dis. 2007; 49(6): 786-92.10.1053/j.ajkd.2007.03.01117533021
38. Tuimlehto J, Rastenyete D, Jousilahti P, Sarti C, Vartianinen E. Diabetes mellitus as a risk factor for death from stroke: prospective study of the middleaged Finnish population. Stroke. 1996; 27: 210-5.10.1161/01.STR.27.2.2108571411
40. Megherbi SA, Mialn C, Minier D, et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke. Data from from the European BIOMED Stroke project. Stroke. 2003; 344: 688-94.10.1161/01.STR.0000057975.15221.40
41. Bonora E, Kiechl E, Oberhollenzer F. Imparied glucose tolerance, Type 2 diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study. Diabetologia. 2000; 43: 156-64.10.1007/s001250050024
42. Grag R, Chaudhuri A, Munscauer F. Hyperglycemia insulin and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke. 20006; 37: 267-73.10.1161/01.STR.0000195175.29487.30
43. Selvin E, Coresh J, Golden SH. Glycemic control, Atherosclerosis, and Risk factors for cardiovascular Disease in Type 2 Diabetes. The Atherosclerosis Risk in Communities.
46. Toni D, Sacchetii Ml, Argentino C, Gentile M, Cavalleti C, Frontoni M, et al. Does hyperglycemia play a role on the outcome of ishemic stroke patients? J Neurol. 1992; 239: 382-6.
48. Pulsinelli WA, Levy DE, Sigsvee B, Scherer P, Plum F. Increased damage after ischemic stroke in patients with hyperglicaemia with or without established diabetes mellitus. Am J Med. 1983; 74: 540-4.10.1016/0002-9343(83)91007-0
49. Peila R, Rodriquez BL, Launer LI. Type 2 diabetes, APOE Gene, and the risk for Dementia and related pathologies. Honolulu Asia-Aging study. Diabetes. 2002; 52: 1256-62.10.2337/diabetes.51.4.125611916953
50. Korf ESC, White LR, Scheltens P, Launer LJ. Brain Aging in Very old men with type 2 diabetes. Diabetes Care. 2006; 29(10): 2268-74.10.2337/dc06-024317003305
52. Fuster V, Ryden LE, Asinger RW, Cannon DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J. 2006; 27: 1979-2030.
53. Gage BF, Waterman AD, Shannon W. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285: 2864-70.10.1001/jama.285.22.2864
54. Wang TJ, Massaro JM, Levy D. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003; 290: 1049-1056.10.1001/jama.290.8.1049
55. Adler A, Stratton I, Neil H. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000; 321: 17: 412-9.10.1136/bmj.321.7258.412
56. Chalmers J, Joshi R, Patel A. Advances in reducing the burden of vascular disease in type 2 diabetes. Clin Exp Pharmacol Physiol. 2008 Apr; 35(4): 434-7.10.1111/j.1440-1681.2008.04892.x
59. The Task Force on Diabetes and Cardiovascular Disease of the European Society of Cardiology and of the European Association of the Study of Diabetes. doi.10.1093/eurheartj/ehl261.
60. Khan NA, Hemmelgarn B, Herman RJ, Rabkin SW, McAlister FA, Bell CM, et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol. 2008; 24(6): 465-75.10.1016/S0828-282X(08)70620-2
62. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med. 2004; 164: 2106-10.10.1001/archinte.164.19.2106
63. Bosevski M, Georgievska Lj, Borozanov V. Dual antithrombotic therapy and hypercoagulability in diabetic patients. Am Heart J. 2008; 155(6): e47.10.1016/j.ahj.2008.03.001
64. Serebruany VL, Malinin AI, Pokov A, Barsness G, Hanley DF. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. Am Heart J. 2008 Jan; 155(1): 93.e1-7.10.1016/j.ahj.2007.10.006
65. Williams LS, Rotich J, Qi R, Fineberg N, Espay N, Bruno A, et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 200259; 67-71 x 68. UKPDS 33. Lancet. 1998; 352: 837-53.
66. Diabetes Prevention Research Programme. reduction in the incidence of type 2 diabetes with lifestyle modification and or metformin. N Engl J Med. 2002; 346: 394-46.
67. Heart protection study Collaboration Group. MRC/BHF Heart Protection Study of cholesterollowering in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003; 361: 2005-16. 67b. Chambers BR, Roberts NG. Asymptomatic carotid artery stenosis. Current Treatment in Cardiovascular Medicine. 2007; 9(2): 81-89.10.1016/S0140-6736(03)13636-7
68. Eton D. Surgery and Medical Management of Cerebrovascular Disease in: Eton D. Vascular Disease: A Multi-Specialty approach to Diagnosis and Management, Landes Bioscience, Austin 1999.
69. Reina-Gutierrez T, Serrano-Hernanado FJ, Sanchez- Hervas L. Recurrent carotid artery stenosis following up endarterectomy: natural history and risk factors. Euro J Vasc Endovasc Surg. 2005; 29(4): 334-41.10.1016/j.ejvs.2004.10.00715749031
70. Tropeano AI, Boutouyrie P, Katsahian S. Glucose level is a major determinant of carotid intima-media thickness in patients with hypertension and hyperglycemia. J Hypertension. 2004; 22(11): 2153-60.10.1097/00004872-200411000-0001815480100
73. Coward Lj, Featherstone RL, Brown MM. Safety and efficacy of endovascular treatment of carotid treatment of carotid artery stenosis compared with carotid endarterectomy: a Cochrane systematic review of the randomized evidence. Stroke. 2005; 36: 905-11.10.1161/01.STR.0000158921.51037.6415746454
74. Hancu N, Cerghizan, Cornelia B. Practical approach to the multifactorial risk in type 2 diabetes. In Cheta D. Multivacsular involvement in Diabetes. Karger, Basel 2005.
75. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR, on behalf of the UKPDS Group. The UKPDS risk engine: a model for the risk the coronary heart disease in type 2 diabetes (UKPDS 56). Clinical Science. 2001; 101: 671-9.10.1042/CS20000335
76. Kothari V, Stevens RJ, Adler AJ, Stratton IM, Manley SE, Neil A, Holman RR, for the UKPDS Group (UKPDS 60) Risk for stroke in the 2 diabetes estimated by UKPDS risk engine. Stroke. 2002; 33: 776-1781.
77. Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabetic Medicine. 2003; 21: 238-245.
79. Haffner SM, Lehot S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229-34.10.1056/NEJM1998072333904049673301
80. Doney A, Lee S, Leese G, Morris A, Palmer C. Increased Cardiovascular Morbidity and Mortality in Type 2 Diabetes Is Associated With Glutathione S Transferase Theta-Null Genotype (A Go-DARTS Study). Circulation. 2005; 111: 677-88.10.1161/CIRCULATIONAHA.104.50922415927971
81. Morrish NJ, Steven LK, Head J, et al. A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO multinational study of vascular disease in diabetics) Diabetologia. 1990, 33: 542-8.10.1007/BF004041422253831
82. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291(3): 335-42.10.1001/jama.291.3.33514734596
83. Orchard TJ, Strandness DE Jr. Assessment of peripheral vascular disease in diabetes. Report and recommendations of an international workshop sponsored by the American Heart Association and the American Diabetes Association Diabetes Care. 1993 Aug; 16(8): 1199-209.10.2337/diacare.16.8.1199
84. De Angelis M, Scrucca L, Leandri M, et al. Prevalence of carotid stenosis in type 2 diabetic patients asymptomatic for cerebrovascular disease. Diabetes Nutr Metab. 2003 Feb; 16(1): 48-55. 84b. Lacroix P, Aboyans V, Criqui MH, Bertin F, Bouhamed T, Archambeaud F, Laskar M. Type 2 diabetes and carotid stenosis: a proposal for a screening strategy in asymptomatic patients. Vascular Medicine. 2006; 11: 93-99.10.1191/1358863x06vm677oa
85. Lorenz MW, Markus HS, Bots MI, et al. prediction of Clinical Cardiovascular Events with Carotid Intima- Media Thickness. Circulation. 2007; 115: 459- 467.10.1161/CIRCULATIONAHA.106.628875
86. Duval M, Altman JJ. When should ultrasonography be used to detect asymptomatic carotid atheroma in diabetic patients? Diabetes Metab. 2006 Dec; 32(6): 638-42. 86b. Bosevski M, Borozanov V, Vavlukis M, Pemovska G, Georgievska-Ismail Lj. Carotid ultrasound, blood lipids and waist determination can predict a future coronary revascularisation in the type 2 diabetic cohort. Prilozi. 2007; 28(2): 127-36.
87. Bernard S, Serusclar A, Targe F, et al. Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects. Diabetes Care. 2005; 28(5): 1158-9.10.2337/diacare.28.5.1158
88. Parikh A, Daneman D. Is Carotid Ultrasound a Useful Tool in Assessing Cardiovascular Disease in Individuals with Diabetes? Diabetes Technology & Therapeutics. 2004; 6(1): 65-9.10.1089/152091504322783440
89. Yokoyama H, Katakami N, Yamasaki Y. Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke. 2006; 37(9): 2420-7.10.1161/01.STR.0000236632.58323.cd
91. Spence JD. Ultrasound measurements of carotid plaques as a surrogate outcome for coronary artery disease. Am J Cardiol. 2002; 89 (suppl): 10B-16B.10.1016/S0002-9149(01)02327-X
92. Giral P, Brucket E, Daiorrou F. Usefulness in predictting coronary artery disease by ultrasonic evaluation of the carotid arteries in asymptomatic hypercholesterolemic patients with positive exercise stress test. Am J Cardiol. 1999; 84: 14-17.10.1016/S0002-9149(99)00184-8
93. Lee EJ, Kim HJ, Bae JM, et al. Relevance of common carotid intima-media thickness and carotid plaque as risk factors for ischemic stroke in patients with type 2 diabetes mellitus. Am J Neuroradiol. 2007; 28(5): 916-9.
94. Giral P, Brucket E, Daiorrou F. Usefulness in predicting coronary artery disease by ultrasonic evaluation of the carotid arteries in asymptomatic hypercholesterolemic patients with positive exercise stress test. Am J Cardiol. 1999; 84: 14-17.10.1016/S0002-9149(99)00184-8
95. Lorenz M, Markus H, Bots M, Rosval M, Sitzer M. Prediction of Clinical Cardiovascular Events with Carotid Intima-media thickness: A systematic review and Meta-analysis. Circulation. 2007; 115: 459-67. 95b. De Angelis M, Strucca L, Leandri M. Prevalence of carotis stenosis in type 2 diabetic pts asymptomatic for cerebrovascular disease. Diabetes Nutr Metab. 2003; 16: 48-55.
96. Bosevski M, Influence of metabolic risk factors for presence of carotid artery disease in patients with type 2 diabetes and coronary artery disease. Diab Vasc Dis Res. 2007; 4(1): 49-52.10.3132/dvdr.2007.00617469044
98. Parikh A, Daneman D. Is Carotid Ultrasound a Useful Tool in Assessing Cardiovascular Disease in Individuals with Diabetes? Diabetes Technology & Therapeutics. 2004; 6(1): 65-9.10.1089/15209150432278344015000773
99. Bosevski M, Peovska I, Georgievska-Ismail L. Noninvasive imaging of diabetic vascular disease. Review in Cardiovascular Medicine 2008; Fall (in press)
100. Ragi P, Bellasi A, Ratti C. Ischemia Imaging and Plaque Imaging in Diabetes. Diabetes Care. 28: 2787-2794, 2005.10.2337/diacare.28.11.278716249559
101. Charvat J, Michalova K, Chlumsky J, Horácková M, Valenta Z, Zdárska D. The significance of carotid artery plaques in the detection of coronary artery disease in asymptomatic type 2 diabetic patients. J Int Med Res. 2006; 34(1): 13-20.10.1177/14732300060340010216604819
102. Mudríková T, Szabová E, Tkác I. Carotid intimamedia thickness in relation to macrovascular disease in patients with type 2 diabetes mellitus. Wien Klin Wochenschr. 2000; 112(20): 887-91.
103. Bernard S, Sérusclat A, Targe F, Charrière S, Roth O, Beaune J, et al. Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects. Diabetes Care. 2005; 28(5): 1158-62.10.2337/diacare.28.5.115815855582
104. Kitagawa K, Hougaku H, Yamagami H, Hashimoto H, Itoh T, Shimizu Y, et al., for OSACA2 Study Group. Carotid intima-media thickness and risk of cardiovascular events in high-risk patients. Results of the Osaka Follow-Up Study for Carotid Atherosclerosis 2 (OSACA2 Study). Cerebrovasc Dis. 2007; 24(1): 35-42.10.1159/00010311417519542
105. Brohall G, Oden A, Fagerberg B. Carotid artery intima-media thickness in patients with type 2 diabetes mellitus and impaired glucose tolerance: a systemic review. Diabetic Medicine. 2005; 23: 609-616.10.1111/j.1464-5491.2005.01725.x16759301
106. Hodis HM, Mack WJ, LaBree L, Seizer RH, Liu CH, Azen SR. The role of carotid intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998; 128: 262-9.10.7326/0003-4819-128-4-199802150-000029471928
107. Yamasaki Y, Kodama M, Nishizawa H, Sakamoto K, Matsuhisa M, Kajimoto Y, et al. Carotid Intima- Media thickness in Japanese Type 2 Diabetic Subjects. Predictors of progression and relationship with incident coronary heart disease. Diabetes Care. 2000; 23(9): 1310-5.10.2337/diacare.23.9.131010977024
108. Salonen R, Nyyssonen K, Porkkala E. Kuopio Atherocslerosis Prevention Study (KAPS). A population- based primary preventive trial of the effect of LDL lowering in atherosclerotic progression in carotid and femoral arteries. Circulation. 1995; 92: 1758- 64.10.1161/01.CIR.92.7.1758
109. Chambless LE, Folsom AR, Davis V, Sharett R, Heiss C, Sortlie P, et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1979-1998. Am J Epidemiol. 2002; 155: 38-47.10.1093/aje/155.1.3811772783
110. Zuriek M, Touboul PJ, Bonithon-Kopp C, Courbon D, Berr C, Leroux C, Ducimetiere P. Cross sectional and 4-year longitudinal associations between brachial pulse pressure and common carotid intimae-media thickness in a general population. The EVA study. Stroke. 2002; 33: 550-5.
111. Mackinnon AD, Jerrard Dune P, Sitzer M, Biehler A, von Kegler S, Markus HS. Rates and determinants of site-specific progression of carotid intima-media thickness: the carotid atherosclerosis progression study (CAPS). Stroke. 2004; 35: 2150-4.10.1161/01.STR.0000136720.21095.f315243147
112. Go AS, Hylek EM, Phillips KA, Chang Y, Henaulst LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-75.10.1001/jama.285.18.237011343485
113. AF Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from the randomized controlled trials. Arch Intern Med. 1994; 154: 1449-57.10.1001/archinte.1994.00420130036007
114. Korf ES, White LR, Scheltens P, Launer LJ. Brain aging in very old men with type 2 diabetes: the Honolulu- Asia Aging Study. Diabetes. 2006; 29(10): 2268-74.
115. Girdia Cb, Avogaro A, Maggini M, Lombardo F, Mannuci E, Turco S, et al. Incidence and risk factors for stroke in type 2 diabetes. Stroke. 2007; 38: 1154- 60.10.1161/01.STR.0000260100.71665.2f17332448
117. Hendbald B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intiamedia thickness and stenosis in non-diabetic subjects. Results from a cross sectional study in Malmo. Sweden. Diabet Med. 2000; 17: 299-307.
118. Brohall G, Oden A, Fagberg B. Carotid artery intima- media thickness in patients with type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabetic Medicine. 2005; 23: 609-16. 118b. Najjar, SS, Scuteri A, Lakatta EG. Arterial aging. Is it an immutable ardiovascular risk factor? Hypertension. 2005; 46: 454-462.